Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT
Royalty Pharma Plc (NASDAQ:RPRX) is one of the top most undervalued biotech stocks to buy now.
Royalty Pharma Plc (RPRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 6,000,000 | $216,180,000 | -4% | 0.36% |
| 2. | Patient Capital Management Samantha Mclemore | 2,987,988 | $107,657,202 | +1% | 4.86% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,976,480 | $107,242,574 | +119% | 0.08% |
| 4. | Viking Global Andreas Halvorsen | 2,597,460 | $93,586,484 | -76% | 0.27% |
| 5. | AQR Capital Management Cliff Asness | 1,736,275 | $62,149,952 | -34% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.51 | 130,000 | $3,836,768.00 | 600,000 | 2023-06-28 | Filing | |
| $32.78 | 45,000 | $1,474,902.00 | 470,000 | 2023-06-13 | Filing | |
| $33.00 | 45,000 | $1,484,946.00 | 425,000 | 2023-06-12 | Filing | |
| $32.25 | 150,000 | $4,837,440.00 | 380,000 | 2023-05-24 | Filing | |
| $32.94 | 69,612 | $2,293,095.85 | 230,000 | 2023-05-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.23 | 33,500 | $1,213,748.55 | 194,848 | 2025-08-11 | Filing | |
| $27.55 | 35,702 | $983,504.42 | 20,099 | 2024-01-04 | Filing | |
| $27.79 | 199,098 | $5,532,276.40 | 55,801 | 2024-01-03 | Filing | |
| $28.52 | 235,200 | $6,707,080.80 | 254,899 | 2024-01-02 | Filing | |
| $28.04 | 65,803 | $1,845,405.65 | 2,477,520 | 2023-12-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 46,604,103 | $1,679,145,924 | 0.11% | |
| 2. | 40,357,821 | $1,454,092,272 | 0.08% | |
| 3. | 36,377,678 | $1,310,687,739 | 0.02% | |
| 4. | 25,428,856 | $916,201,678 | 0.02% | |
| 5. | 21,880,620 | $788,358,739 | 0.14% |
News See All
10 Most Undervalued Biotech Stocks to Buy Now
On July 25, Salveen Richter, Goldman Sachs' lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the biotech sector and what to expect from the earnings season, among...
Royalty Pharma plc (NASDAQ:RPRX) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to Royalty Pharma's Second Quarter 2025 Earnings Conference Call.
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating
Royalty Pharma plc (NASDAQ:RPRX) is one of the high-margin pharma stocks to buy now.
10 Best High-Margin Pharma Stocks to Buy Now
The pharmaceutical sector continues to stand out as a resilient and highly profitable corner of the market, even amid global economic uncertainty.
Royalty Pharma plc (NASDAQ:RPRX) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter Earnings Conference Call.
Royalty Pharma PLC (RPRX) Surged Following an Acquisition Announcement
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
8 Most Undervalued Healthcare Stocks to Buy According to Analysts
Healthcare prices and expenditures have been rising in the United States.
7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
15 Best Defensive Stocks Amid Market Volatility
With ongoing inflation, economic uncertainty, and global tensions, more investors are looking for ways to protect their money while still earning steady returns.